Left Ventricular Dysfunction - Pipeline Review, H1 2019

Global Markets Direct’s, ‘Left Ventricular Dysfunction - Pipeline Review, H1 2019’, provides an overview of the Left Ventricular Dysfunction pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Left Ventricular Dysfunction, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Left Ventricular Dysfunction and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape of Left Ventricular Dysfunction

- The report reviews pipeline therapeutics for Left Ventricular Dysfunction by companies and universities/research institutes based on information derived from company and industry-specific sources

- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

- The report reviews key players involved Left Ventricular Dysfunction therapeutics and enlists all their major and minor projects

- The report assesses Left Ventricular Dysfunction therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type

- The report summarizes all the dormant and discontinued pipeline projects

- The report reviews latest news related to pipeline therapeutics for Left Ventricular Dysfunction

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

- Identify and understand important and diverse types of therapeutics under development for Left Ventricular Dysfunction

- Identify potential new clients or partners in the target demographic

- Develop strategic initiatives by understanding the focus areas of leading companies

- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

- Devise corrective measures for pipeline projects by understanding Left Ventricular Dysfunction pipeline depth and focus of Indication therapeutics

- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Companies mentioned

Bayer AG

Innopharmax Inc

Mesoblast Ltd

Quantum Genomics SA

Takeda Pharmaceutical Co Ltd

Bayer AG

Innopharmax Inc

Mesoblast Ltd

Quantum Genomics SA

Takeda Pharmaceutical Co Ltd

Table of Contents

Table of Contents

List of Tables

List of Figures

Introduction

Global Markets Direct Report Coverage

Left Ventricular Dysfunction - Overview

Left Ventricular Dysfunction - Therapeutics ...

Table of Contents

List of Tables

List of Figures

Introduction

Global Markets Direct Report Coverage

Left Ventricular Dysfunction - Overview

Left Ventricular Dysfunction - Therapeutics Development

Pipeline Overview

Pipeline by Companies

Products under Development by Companies

Left Ventricular Dysfunction - Therapeutics Assessment

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Left Ventricular Dysfunction - Companies Involved in Therapeutics Development

Bayer AG

Innopharmax Inc

Mesoblast Ltd

Quantum Genomics SA

Takeda Pharmaceutical Co Ltd

Left Ventricular Dysfunction - Drug Profiles

AlloCSC-01 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

carvedilol CR - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

firibastat IR - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

fulacimstat - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

MPC-150IM - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

NP-202 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

VBC-01 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Left Ventricular Dysfunction - Dormant Projects

Left Ventricular Dysfunction - Discontinued Products

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List of Tables

List of Tables

Number of Products under Development for Left Ventricular Dysfunction, H1 2019

Number of Products under Development by Companies, H1 2019

Products under ...

List of Tables

Number of Products under Development for Left Ventricular Dysfunction, H1 2019

Number of Products under Development by Companies, H1 2019

Products under Development by Companies, H1 2019

Number of Products by Stage and Target, H1 2019

Number of Products by Stage and Mechanism of Action, H1 2019

Number of Products by Stage and Route of Administration, H1 2019

Number of Products by Stage and Molecule Type, H1 2019

Left Ventricular Dysfunction - Pipeline by Bayer AG, H1 2019

Left Ventricular Dysfunction - Pipeline by Innopharmax Inc, H1 2019

Left Ventricular Dysfunction - Pipeline by Mesoblast Ltd, H1 2019

Left Ventricular Dysfunction - Pipeline by Quantum Genomics SA, H1 2019

Left Ventricular Dysfunction - Pipeline by Takeda Pharmaceutical Co Ltd, H1 2019

Left Ventricular Dysfunction - Dormant Projects, H1 2019

Left Ventricular Dysfunction - Discontinued Products, H1 2019

List of Figures

List of Figures

Number of Products under Development for Left Ventricular Dysfunction, H1 2019

Number of Products under Development by Companies, H1 2019

Number of ...

List of Figures

Number of Products under Development for Left Ventricular Dysfunction, H1 2019

Number of Products under Development by Companies, H1 2019

Number of Products by Targets, H1 2019

Number of Products by Stage and Targets, H1 2019

Number of Products by Mechanism of Actions, H1 2019

Number of Products by Stage and Mechanism of Actions, H1 2019

Number of Products by Routes of Administration, H1 2019

Number of Products by Stage and Routes of Administration, H1 2019

Number of Products by Molecule Types, H1 2019

Number of Products by Stage and Molecule Types, H1 2019

    Pricing

Discounts available for multiple report purchases.

reportstore@globalmarketsdirect.com
+44 (0) 161 359 5414

Saved reports